A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

NCT06097663 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Heart Disease
Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Interventions

DRUG: MAS825
DRUG: MAS825 Placebo
DRUG: DFV890
DRUG: DFV890 placebo

Sponsor

Novartis Pharmaceuticals